We thank Dr Yu and colleagues for their letter. We agree that the presence of baseline NS5A resistance-associated substitutions in patients with hepatitis C virus genotype 2 infection reduces the efficacy of ultrashort durations of ledipasvir-sofosbuvir. This is particularly pertinent for patients infected with subtype 2a, where the “wild type” virus seems to harbor NS5A resistance-associated substitutions (10/11 treatment-naïve patients had either K30R and/or L31M at baseline).